News Search:
Enanta Pharmaceuticals, Inc. Initial Public Offering
Davis Polk advised J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC as joint book-running managers of the several underwriters in connection with the initial public offering of 4,600,000 shares of common stock of Enanta Pharmaceuticals, Inc. for approximately $60 million. The common stock is listed on The NASDAQ Global Select Market under the symbol “ENTA.”

Based in Watertown, Massachusetts, Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta Pharmaceuticals, Inc. is discovering and developing novel inhibitors designed for use against the hepatitis C virus.

The Davis Polk corporate team included partner Richard D. Truesdell Jr. and associates Jonathan C. Pentzien and Kavita Paw. The intellectual property team included partner Frank J. Azzopardi and associates David R. Bauer and Bruce Rose-Innes. Partner Samuel Dimon and associate Juelle Gomes provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. Anney Chi was the legal assistant for the transaction. All members of the Davis Polk team are based in the New York office.